You may also experience skin tightness and mild sensitivity to touch
Eli Lilly (NYSE: LLY) and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and obesity
This is especially relevant for those who have already achieved a stable regimen and do not want to lose results due to logistics delays
In practice, both options can be effective, success largely depends on consistency, proper dosing, and accompanying lifestyle adjustments such as balanced meals and physical activity
Results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) demonstrate that although the prevalence of stroke and age-standardized death rate have decreased as time goes by, there has recently been a significant increase in the numbers of people dying from and affected by stroke, resulting in greater loss of health over the lifespan (5)